Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 463

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 19
Chunk 463
---
 ​   ​           17,499      ​      ​          15,101   ​   ​    ​       
Total property, plant and equipment                                         ​   ​       ​          ​   €           122,898     ​      €         126,321   ​   ​    ​       
​
The sales and disposals of 2023 mainly relate to the transaction with NovAlix. We refer to note 29 “Details of the NovAlix transaction” for more information. The sales and disposals of 2024 mainly relate to the disposal of rented cars.We refer to note 25 Lease liabilities for a detail of the lease liabilities related to these right-of-use assets.There are no pledged items of property, plant and equipment. There are also no restrictions in use on any items of property, plant and equipment.

F-44

16. Equity investments​

                 ​                     ​   ​    ​       ​       ​      ​       ​   
-----------------------------------------------------------------------------------
​                                      ​   ​   ​                       December 31,
​                                          2024                2023                
​                                      ​   ​   (Euro, in thousands)                
Cost at January 1                      ​   ​   €      13,965   ​      €      —     
Acquisitions of the year               ​   ​   ​      36,880   ​      ​      13,965
Cost at December 31                    ​   ​   ​      50,845   ​      ​      13,965
​                                      ​   ​   ​           ​   ​      ​      ​     
Fair value adjustment at January 1     ​   ​   ​       (390)   ​      ​      —     
Fair value adjustment of the year      ​   ​   ​       2,485   ​      ​      (390) 
Fair value adjustment at December 31   ​   ​   ​       2,095   ​      ​      (390) 
Net book value at December 31          ​   ​   €      52,941   ​      €      13,575
​
On December 31, 2023, we had $15.0 million of equity investment in a non-listed company.
On January 31, 2024, we participated for $40.0 million in the Series C financing round of Frontier Medicines, a pioneer in oncology with a unique FrontierTM platform based on chemoproteomics, covalent chemistry and machine learning to unlock access